Aprocitentan - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for aprocitentan and what is the scope of freedom to operate?
Aprocitentan
is the generic ingredient in one branded drug marketed by Idorsia and is included in one NDA. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for aprocitentan
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 8 |
What excipients (inactive ingredients) are in aprocitentan? | aprocitentan excipients list |
DailyMed Link: | aprocitentan at DailyMed |
Recent Clinical Trials for aprocitentan
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Actelion | Phase 1 |
Idorsia Pharmaceuticals Ltd. | Phase 1 |
Janssen Biotech, Inc. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for aprocitentan
US Patents and Regulatory Information for aprocitentan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |